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ORIGINAL ARTICLE
beta-Adrenoreceptor antagonists reduce cancer cell proliferation,
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Faik Sarialioglu5
1Institute of Transplantation and Gene Sciences, Baskent University, Ankara, Turkey, 2Department of Medical Genetics, 3Department of Medical
Biology, 4Department of Pharmacology, and 5Department of Pediatrics, Faculty of Medicine, Baskent University, Ankara, Turkey
Abstract
Context: Propranolol, atenolol, and ICI118,551 are non-selective b-adrenergic receptor (AR), b1-
AR, and b2-AR antagonists, respectively.
Objective: We investigated the efficacy of propranolol, atenolol, and ICI118,551 on proliferation,
migration, and invasion of non-stimulated breast (MCF7), colon (HT-29), and hepatocellular
(HepG2) cancer cells.
Materials and methods: b-AR expression profiling of cells was performed by real time PCR. Cell
proliferation was determined by MTT. Boyden chamber and scratch assays were performed to
evaluate invasion and migration.
Results and discussion: All cell lines expressed b-ARs. ICI118,551 was the most cytotoxic, whereas
atenolol was the least effective b-AR antagonist for 24, 48, and 72 h. Cell invasion was inhibited
by ICI118,551 (45, 46, and 50% for MCF7, HT29, and HepG2, respectively) and propranolol (72,
65, and 90% for MCF7, HT29, and HepG2, respectively). Propranolol, atenolol, and ICI118,551
reduced migration of MCF7, HT-29, and HepG2 cells to varying extents depending on the
application concentration and duration. Propranolol and atenolol reduced migration of MCF7
and HT-29 in a concentration-dependent manner, whereas migration of these cells decreased
after 48 and 72 h of ICI118,551 applications.
Conclusion: Beta2-AR antagonist seemed to be the most cytotoxic b-blocker on non-stimulated
cancer cells. Propranolol and ICI118,551 were more effective than atenolol in inhibiting invasion
and migration of non-stimulated MCF7 and HT-29 cells; ICI118,551 being the most potent.
Concordantly, b2-selective blockage seemed to be more effective for non-stimulated cells.
Effect of the selective b-AR antagonists showed variation depending on the concentration,
incubation time, and histological origin of cells.
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Introduction
Norepinephrine and epinephrine, the catecholamines released
from the central and sympathetic nervous system neurons, and
from the adrenal medulla, are the endogenous natural ligands
for adrenergic receptors (ARs). ARs are members of a large
seven-transmembrane (7TM) superfamily of receptors linked
to guanine–nucleotide-binding proteins (reviewed in Insel,
1996). Two principal types of ARs with nine subtypes, six
subtypes of a-adrenergic (a1A, a1B, a1D, a2A, a2B, and a2C),
and two subtypes of b-adrenergic (b1, b2, and b3), have been
identified based on the tissue distribution, function, and
structure (Insel, 1996; Kyprianou & Benning, 2000; Zhang
et al., 2009). In addition to their crucial roles in the
neuroendocrine and hemodynamic functions, they modulate
diverse cellular processes, such as DNA synthesis and
cytoskeletal protein function. Binding of a ligand to the
extracellular face of a 7TM receptor causes transformation of
the signal into a complex network of intracellular signals
through interaction with transducer G proteins and their
effectors at the intracellular face (reviewed in Nygaard et al.,
2009; Wallukat, 2002). Beta-AR stimulation through this
transmembrane allosteric mechanism can initiate multiple
signaling cascades, including the cAMP/PKA, MAPK/ERK1/2,
p38/MAPK, PI3K/AKT, VEGF, Src/STAT pathways, and
arachidonic acid (AA) cascade (reviewed in Wallukat, 2002).
Stimulation of b-ARs in tumor cells induces cancer cell
growth and invasion via arachidonic acid cascade, particularly
through the activation of cyclooxygenase-2 (COX-2) (Wong
et al., 2007; Yuan et al., 2010).
Although the complex process and mechanism of metas-
tasis have not been well understood to date, host factors in
the tumor environment are believed to be involved.
Norepinephrine-induced migration and invasion of carcinoma
cells through b-AR stimulation with increased expression of
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vascular endothelial growth factor, matrix metalloproteinase
(MMP)-2, and MMP-9 have been demonstrated in a number
of cell lines (Drell et al., 2003; Masur et al., 2001; Schuller &
Cole, 1989; Sood et al., 2006; Yang et al., 2006).
b-AR antagonists block receptor activation. There have
been three generations of b-AR antagonists, classified based
on their pharmacological properties. Among these, first
generation b-AR antagonists constitute non-selective b1/b2
blockers, such as propranolol which is commonly used for the
treatment of hypertension. There is growing clinical evidence
on the efficacy and use of propranolol in treating severe
infantile hemangiomas (Erbay et al., 2010; Leaute-Labreze
et al., 2008; Sarialioglu et al., 2010). Emergence of evidence
on the role of b-AR stimulation in hemangiomas and tumor
cells raised the question whether b-AR blockers play regu-
latory roles in the cancer cell proliferation and migration/
invasiveness. Pre-clinical studies demonstrated that inhibition
of norepinephrine stimulation of lung adenocarcinoma and
colon carcinoma, ovarian, and pancreatic cancer cells by
propranolol exerted anti-proliferative, anti-migratory, and
cytotoxic effects on cells (Guo et al., 2009; Masur et al.,
2001; Schuller & Cole, 1989; Sood et al., 2006). Moreover,
both b1-selective (atenolol) and b2-selective (ICI118,551)
adrenoceptor antagonists have been shown to reverse nico-
tine-induced tumor growth in colon cancer xenograft mice
(Wong et al., 2007). Recent clinical evidence revealed that the
use of beta-blockers, prior to diagnosis or concurrently with
chemotherapy, could increase survival, and decrease metas-
tasis rates in cancer patients (Barron et al., 2011; London &
McGlynn, 2012; Powe et al., 2010).
Previous findings mainly emphasize the inhibitory effect of
b-AR blockers on the norepinephrine/epinephrine-induced
cell proliferation and migration. However, there is limited
evidence on the cytotoxicity of these selective and non-
selective b-AR antagonists and sole chemotherapeutic effect
on cancer cells. In the present study, we aimed to investigate
direct effects of propranolol, a non-selective b-AR antagonist,
atenolol, a selective b1-AR antagonist, and ICI118,551, a
selective b2-AR antagonist on cell proliferation, migration,
and invasion of breast (MCF7), colon (HT-29), and
hepatocellular (HepG2) non-stimulated cancer cells for the
in vitro demonstration of potential cytotoxicity and efficiency
of beta-blockers.
Materials and methods
Cell lines and culture conditions
HTB-22 (MCF7) human breast adenocarcinoma cells were
obtained from HUKUK (S¸AP Institute, Ankara, Turkey),
HTB-38 (HT-29) human colorectal adenocarcinoma, and HB-
8065 (HepG2) human hepatocellular carcinoma cells were
obtained from ATCC (Rockville, MD). MCF7 cells were
maintained in RPMI-1640 medium, HT-29 cells were main-
tained in McCoy’s-5A medium (Biochrom AG, Berlin,
Germany) and HepG2 cells were maintained in Dulbecco’s
minimal essential medium (DMEM) (Biochrom AG). All
media were supplemented with 10% heat-inactivated fetal
bovine serum (FBS, Biochrom AG), L-glutamine (Biochrom
AG), and streptomycin–penicillin (Biological Industries,
Kibbutz Beit-Haemek, Israel). Incubation conditions at
37 C in a humidified atmosphere of 5% CO2 were maintained
in a Heraeus incubator (Hanau, Germany).
Assay for antiproliferative effect (MTT assay)
The effects of propranolol (Sigma Aldrich, St. Louis, MO),
atenolol (Sigma), and ICI118,551 (Sigma) on the proliferation
of all cell lines were colorimetrically tested by biochemical
reduction of MTT [3-(4,5-dimethyl-2-thiazol-2-yl)-2,5-diphe-
nyl-2H-tetrazolium bromide; Sigma-Aldrich, St. Louis, MO].
The compounds were diluted from high to low concentrations
horizontally in 96-well microtiter plates. Cells were seeded to
each well (1 105) with the exception of medium controls.
The plates were incubated for 24, 48, or 72 h and then 20 mL
of MTT solution (5 mg/mL) was added to each well. After
incubation for 4 h, 100 mL acidic sodium dodecyl sulfate
(Sigma-Aldrich, St. Louis, MO) solution (10% w/v) was
added to each well. The plates were further incubated
overnight to allow the dissolution of formazan crystals that
were produced by mitochondrial activity of the viable cells.
The inhibition of cell proliferation was determined by
measuring the optical density of the chromogenic product at
540 nm with an ELISA reader (Biotek Instrument ELx800,
Winooski, VT). Inhibitory concentration 50 (IC50; the drug
concentration at which 50% of the cells are viable) values
were calculated from the logarithmic trend lines of cell
proliferation graphs. Assays were performed as at least
triplicate independent experiments.
Analyses of AR gene expression (real-time PCR
analyses)
Total RNA was isolated from MCF7, HT-29, and HepG2 cell
lines with TriPure isolation reagent according to the manu-
facturer’s instructions (Roche Diagnostics GmbH, Mannheim,
Germany). The quality and quantity of RNA were determined
by using NanoDrop 2000 Spectrophotometer (Thermo
Scientific, Wilmington, DE). One microgram of total RNA
was reverse transcribed using Transcriptor First Strand cDNA
Synthesis Kit (Roche Diagnostics GmbH, Mannheim,
Germany). Real-time ready catalog assays which are short
FAM-labeled hydrolysis probes containing locked nucleic
acid were used for RT-PCR reactions (Roche Diagnostics
GmbH, Mannheim, Germany). Expression of beta (ADRA1B-
Assay ID: 100800 and ADRA2B-Assay ID: 100801) and
alpha (ADRA1A-Assay ID: 113884 and ADRA2A-Assay ID:
114264) ARs were determined using a semi-quantitative
RT-PCR by Light Cycler 480 II system (Roche Diagnostics
GmbH, Mannheim, Germany) according to the manufac-
turer’s instructions with a pre-incubation step at 95 C for
10 min, followed by 45 cycles at 95 C for 10 s, 60 C for 30 s,
and 72 C for 1 s. TBP (Assay ID: 101145) were used for
normalization of the expression data. Semi-quantitative PCR
reactions were run in triplicate, and the expressions of
ADRA1A, ADRA2A, ADRA1B, and ADRA2B were determined
in MCF7, HT-29, and HepG2 cell lines.
Cell invasion assay
Cell invasion was determined using the CytoSelect cell
invasion assay (Cell Biolabs, San Diego, CA) according to the
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manufacturer’s instructions. Briefly, cells were serum-starved
for 24 h. Basement membranes of Boyden chambers were
rehydrated with 300mL serum-free medium, and 1 106 cells
in appropriate serum-free medium were seeded into the upper
chamber containing antagonists or agonist (isoproterenol, a
non-selective agonist) for b adrenoceptors. Bottom wells were
filled with medium supplemented with 10% FBS. Propranolol
concentrations were 150, 50, and 15 mM for MCF7, HT-29,
and HepG2 cells, respectively. Atenolol concentrations were
600mM MCF7 and HT-29, and 2400 mM for HepG2 cells.
About 90, 20, and 10 mM ICI118,551 were applied to MCF7,
HT-29, and HepG2 cells, respectively. Ten mM isoproterenol
(Sigma) were applied (Lung et al., 2005; Yang et al., 2009).
After 24 h incubation (37 C, 5% CO2), non-invasive cells
were removed from the upper chamber and cell invasion was
assessed by light microscopy after staining of invaded cells
with cell stain solution. For colorimetric quantification of
invasion, inserts were then placed in extraction buffer
(200mL, for 10 min), and absorbance (A) at 560 nm was
determined after transfer to a 96-well plate (100mL/well)
using an ELISA reader (Biotek Instrument ELx800,
Winooski, VT). Changes in cell invasion due to antagonist
and isoproterenol applications were expressed as percent
relative to untreated control as follows:
Invasion ð%Þ ¼ Atreatment=Acontrolð Þ  100
All assays were performed as duplicates.
In vitro scratch assay
The in vitro scratch-wound healing assay was used to study
cell migration. Cells were seeded in a six-well plate at a
density of 1 106 cells per well. Linear scratch wounds were
made in the cell monolayer using a pipette tip. Scratch
wounds were then visualized using an Olympus CK40
inverted microscope, and baseline photomicrographs were
captured by a digital camera (Eclips E600, Nikon, Kanagawa,
Japan). Receptor antagonists and isoproterenol were applied
into separate wells. Propranolol concentrations were 100, 150,
and 200 mM for MCF7; 50, 100, and 150mM for HT-29
and 10, 20, and 50 mM for HepG2 cells. Atenolol concentra-
tions were 200, 400, and 600 mM for MCF7; 400, 600, and
800mM for HT-29; and 800, 1000, and 1500 mM for HepG2
cells. About 50 and 100 mM ICI118,551 for MCF7; 25 and
50 mM for HT-29; and 10 and 20 mM for HepG2 cells were
applied. Isoproterenol was applied at 10 mM concentration
(Lung et al., 2005; Yang et al., 2009) to all cell lines. Scratch
wounds were captured at 24 h intervals during 72 h time. The
areas of the scratch-wounds were analyzed by ImageJ
software (National Institutes of Health, Bethesda, MD). For
quantification, the distance between the wound edges was
measured at least 10 random points, and the mean values were
calculated (d). The percentage of wound healing (WH) was
calculated as
% WH ¼ doriginal wound  dhealing
 
=doriginal wound
  100
Statistical analyses
Homogeneities of data were controlled by Levene’s test.
The normality of distributions of the variables was analyzed
by the Kolmogorov–Smirnov test. The results of the
normality test and homogeneity test were used to decide
which statistical methods to apply in comparing groups.
Normal distributed groups were compared by means of
independent samples and Student’s t-test, and the results were
expressed as ± Sx: mean ± standard error of the means. Non-
normal distributed groups with heterogeneous variances were
compared by means of the Mann–Whitney U-test, and the
results were expressed as ± Sx: mean ± standard error of
mean. A two-proportion z-test and the Fisher exact test were
used for comparing the ratios. Value of p less than 0.05 was
considered to be statistically significant. Statistical analyses
were performed by SPSS 17.0 and MINITAB 13.0 statistical
software programs (SPSS Inc., Chicago, IL).
Results
Antiproliferative effects of b-AR antagonists on MCF7,
HT-29, and HepG2 cells
MTT findings demonstrated that propranolol caused a
concentration-dependent reduction in proliferation of MCF7,
HT-29, and HepG2 cells. As displayed in Table 1, after 24 h
incubation, propranolol was more cytotoxic on HT-29 and
HepG2 cells than it was on MCF7 (p50.05). However,
cytotoxicity of propranolol on MCF7 and HT-29 cell lines
increased with increasing incubation periods (p50.05).
Results obtained after 72 h of incubation were indifferent
for the cell lines.
Atenolol application caused concentration-dependent
reductions in cell proliferation in all cell lines. However,
according to IC50 values, atenolol was found to be less
cytotoxic at all cell lines tested when compared with
propranolol (Table 1) (p50.05). In addition, cytotoxicity of
atenolol increased with increasing incubation periods
(p50.05). IC50 obtained with HepG2 cell line was signifi-
cantly higher than that of MCF7 and HT-29 cell lines
(p50.05).
MTT results demonstrated high cytotoxicity of ICI118,551
on three cell lines tested. Cytotoxicity of ICI118,551 on
MCF7 cell line increased after 48 and 72 h when compared
with 24 h (p50.05). In contrast, IC50 values obtained after 24,
48, and 72 h for HT-29 and HepG2 cell lines were statistically
indifferent (p40.05).
Table 1. IC50 values for propranolol, atenolol, and ICI118,551.
IC50 (mM) ± SEM
a
24 h 48 h 72 h
MCF7 Propranolol 157.6 ± 2.6 51.3 ± 5.2 30.0 ± 6.2
Atenolol 579.0 ± 38.9 437.5 ± 8.9 223.3 ± 29.9
ICI118,551 87.6 ± 5.5 25.0 ± 3.3 25.7 ± 0.2
HT-29 Propranolol 56.9 ± 2.9 42.8 ± 2.6 20.10 ± 4.9
Atenolol 599.2 ± 87.7 470.5 ± 26.1 277.2 ± 41.9
ICI118,551 21.9 ± 1.5 25.2 ± 0.7 25.8 ± 1.0
HepG2 Propranolol 15.40 ± 2.4 21.0 ± 5.8 27.81 ± 5.2
Atenolol 2023.8 ± 108.2 1540.0 ± 276.8 1346.5 ± 92.9
ICI118,551 11.6 ± 0.4 12.0 ± 0.6 11.6 ± 0.4
aSEM (standard error of the means) was derived from at least three
independent experiments.
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MCF7, HT-29, and HepG2 cells expressed both b1- and
b2-AR genes
The real-time PCR analysis demonstrated that all the cell lines
expressed b1- and b2-AR genes (ADRA1B and ADRA2B,
respectively). In addition, MCF7 and HepG2 cells expressed
a1- and a2-AR genes (ADRA1A and ADRA2A, respectively).
ADRA1A expression was not determined in HT-29 cells.
qRT-PCR analysis (Figure 1) revealed that alpha and beta
ARs show different expression pattern in MCF7, HT-29, and
HepG2 cell lines. Low level of ADRA1A expression was
detected in MCF7 and HepG2 cells, but we could not detect
ADRA1A expression in HT-29 cells. The highest expression of
ADRA2A and ADRA2B was found in HT-29 cell line.
ADRA2A and ADRA2B genes expressed in HT-29 cells
approximately 110- and 3-fold higher than MCF7 cells, and
570- and 14-fold higher than HepG2 cells, respectively.
In contrast, the ADRA1B expression was found to be higher in
MCF7 cells, which is expressed 2-fold higher than HT-29
cells and 10-fold higher than HepG2 cells.
Propranolol and ICI118,551 caused reduction in
carcinoma cell invasion
The invasiveness of tumor cells was measured by the Boyden
chamber-based cell invasion assay. Invasive cells were
discriminated from non-invasive cells based on their ability
to degrade basement membrane-coated layer and pass through
the pores of membrane (Albini et al., 1987). The findings
obtained from the assay were expressed in terms of percent
invasion relative to invasion of non-treated control cells after
24 h (Table 2). Accordingly, the invasiveness of MCF7, HT-
29, and HepG2 cells was significantly inhibited (p50.05) by
24 h propranolol and ICI118,551 applications. Among the cell
lines tested, propranolol exerted highest reduction in
invasiveness of HT-29 cells (66%). In contrast, the effects
of ICI118,551 on invasiveness of three cell lines were similar,
but higher than that of propranolol (in a range of 44–51%).
Atenolol, in contrast, did not seem to exert significant effect
(p50.05) on invasiveness of MCF7, HT-29, and HepG2 cells
(i.e., invasiveness were higher than 93% all the cell lines).
Although isoproterenol seemed to increase invasiveness of
cells, only the finding obtained with HepG2 cells was
statistically significant (127%; p50.05).
Effects of antagonists on carcinoma cell migration
In vitro migration properties of tumor cells were determined
by the wound-healing assay. The assay mimics cell migration
during wound healing in vivo (Figure 2). Wound-healing at
every 24 h for 72 h was expressed as percent wound-healing
relative to the original scratch (Figure 3). Accordingly,
100 mM propranolol caused significant reduction (p50.05)
in migration of MCF7 cells after 48 and 72 h. Increasing
propranolol concentration to 150 and 200 mM caused further
reduction (p50.05) in migration. Atenolol (200mM) signifi-
cantly inhibited MCF7 migration at all application periods,
and WH of cells were significantly lower when 600 mM
atenolol was applied (p50.05). ICI118,551 (100 mM) inhib-
ited MCF7 cell migration after 48 and 72 h (p50.05).
Propranolol inhibited migration of HT-29 cells (p50.05).
Doubling the propranolol concentration from 50 to 100 mM
caused significant reduction in migration (p50.05). Atenolol
(400 mM) application caused significant reduction of HT-29
migration in all time periods tested (p50.05). Doubling the
atenolol concentration from 400 to 800 mM caused significant
reduction in migration after 24 and 72 h (p50.05).
ICI118,551 inhibited HT-29 cell migration after 48 and 72 h
(p50.05) of application periods. Doubling the ICI118,551
0 h 24 h 72 h48 h
Figure 2. Representative micrographs for wound healing assay (4).
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Figure 1. qRT-PCR analysis of ARs in MCF7, HT-29, and HepG2 cell
lines.
Table 2. Effects of b-AR antagonists and isoprotrenol on invasion of
MCF7, HT-29 and HepG2 cells incubated for 24 h. Changes in cell
invasion due to antagonist and isoproterenol applications were expressed
as percent relative to untreated control.
% Invasion (relative to non-treatment control) ± SEMa
Cell line Propranolol Atenolol ICI118,551 Isoproterenol
MCF7 72.0 ± 0.2* 93.8 ± 0.6 44.3 ± 5.2* 104.1 ± 14.8
HT-29 65.5 ± 0.4* 93.7 ± 2.9 46.0 ± 3.8* 109.5 ± 9.50
HepG2 88.8 ± 1.2* 95.9 ± 2.3 50.6 ± 0.8* 126.9 ± 11.6*
aSEM (standard error of the means) was derived from two experiments.
*Represents significant difference (p50.05) in mean invasiveness of the
treatment group in comparison to control.
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concentration from 25 to 50 mM did not cause reduction in
migration (p50.05). Propranolol caused reduction in wound-
healing of HepG2 cells in 48 and 72 h (p50.05), and the
inhibitory effects were concentration independent (p40.05).
Eight hundred micromolar atenolol inhibited HepG2 cell
migration at all time periods tested (p50.05). Increased
atenolol concentrations had no effect on migration of
HepG2 cells (p40.05) except for the 24 h applications. In
addition, ICI118,551 inhibited HepG2 cell migration in all
time periods tested (p50.05). WH of cells were differed
among 24, 48, and 72 h applications at both 10 and 20 mM
(p50.05), although there was no significant difference
between two concentrations (p40.05). Effects of 10 mM
isoproterenol on migration characteristics in the cell lines
were also tested. Isoproterenol seemed to have no significant
effect on wound-healing capacity of the cell lines tested (data
not shown).
Discussion
The cytotoxic potential of b-blockers has been studied
previously on different cell lines. In particular, propranolol
has been shown to reduce mitogenic activity of pancreatic,
leukemia, and oral squamous cancer cells mainly via b2-ARs
(Hajighasemi & Mirshafiey, 2009; Shang et al., 2009; Zhang
et al., 2009). Previous studies showed that propranolol acts as
Gi-independent manner (Galandrin et al., 2008) to inhibit cell
proliferation and induce apoptosis through different down-
stream molecules which participate in Ras/Akt, Src tyrosine
kinase, MAPKs, ERK1/2, and PKA/AA pathways
(Hajighasemi & Mirshafiey, 2009; Shang et al., 2009;
Zhang et al., 2009). In particular, induction of apoptosis of
pancreatic cancer cell line by propranolol was well char-
acterized by stimulation of proteolytic activities of caspase-3
and caspase-9, and the intrinsic pathway (Zhang et al., 2009).
Isoproterenol is a non-selective b-AR agonist acting via
adenylyl cyclase (AC) and MAPK. Both Gi-independent
and dependent pathways contribute to the response to
isoproterenol. For example, bucindolol and propranolol
share the same Gi-independent MAPK signaling pathway,
but they have opposite effects in terms of AC activity
(Galandrin et al., 2007). So, two downstream signaling
responses, by distinguishing two compounds, may further
contribute to ligand selectivity. Although ERK1/2 activation
is one of the downstream effectors of AC signaling, two
pathways can be independently regulated. Isoproterenol is an
agonist for these two systems, ERK1/2 activation via
isoproterenol stimulation being independent of cAMP gener-
ation. Interestingly, propranolol acts as an inverse agonist for
AC, and partial agonist for ERK1/2. Both isoproterenol and
propranolol act on a common Gi-independent pathway;
however, activation of different downstream effectors, like
ERK1/2, may have distinct consequences on gene regulation
and cell proliferation (Galandrin et al., 2008).
Results of the present study demonstrated that the non-
selective b-blocker propranolol was more cytotoxic to all cell
lines than b1-blocker atenolol, but less cytotoxic than
b2-blocker ICI118,551 (Table 1). IC50 of propranolol
were approximately 2-fold of that of ICI118,551 for all
cell lines and incubation periods. However, atenolol to
propranolol IC50 ratios varied 4–80 fold, and atenolol to
ICI118,551 IC50 ratios varied 6–120 fold depending on the
cell line and incubation period. Cheong et al. (2008) and
Weddle et al. (2001) studied cytotoxicity of different
b-blockers on immortalized retinal and corneal cells, and
pancreatic cancer cells, respectively. Both the studies reported
atenolol as the least cytotoxic among the b-blockers studied.
In another study, ICI118,551 and atenolol were applied to
nicotine-stimulated colon carcinoma cells, and both agents
were shown to inhibit cell proliferation. b2-Adrenergic
receptor mediated more dominant effect in these applications
(Wu et al., 2005). Likewise, ICI118,551 inhibited DNA
synthesis of unstimulated pancreatic adenocarcinoma cells,
whereas atenolol did not (Weddle et al., 2001). Furthermore,
ICI118,551 was more effective in tumor growth inhibition
than atenolol as demonstrated in mouse xenograft of colon
carcinoma (Wong et al., 2007).
In the study of Zhang et al. (2011), ICI118,551 caused
inhibition of pancreatic carcinoma cell proliferation, induc-
tion of apoptosis, and G1/S phase arrest. They also found that
these effects were stronger than the b1-AR antagonist
metoprolol. These effects were associated with the down-
regulation of cyclin D1 and cyclin E by ICI118,551.
Meanwhile, limited activation of Bax, caspase-9, and
caspase-3, and suppression of the ERK and Akt pathways
which phosphorylate Bad, and allows Bcl-2 to form homo-
dimers which may affect antiapoptotic response of cells of
different histological origins. Suppression of the NF-kB
activation in cells through any upstream effectors may also
cause attenuated sensitivity of cells at transcriptional level. In
fact, cells of different histological origins have variable
sensitivity to apoptosis which is also related to chemoresis-
tance of cells due their differences at genomic or transcrip-
tional level.
Although cytotoxicity ratios did not seem to correlate with
b1- and b2-AR mRNA expression levels in cells, b2-blocker
seemed to be more cytotoxic in non-stimulated cancer cells
than b1-blocker and even non-selective b-blocker that act via
both types of receptors. In fact, native (non-stimulated) b-ARs
occurring in glioma cells were shown to be constitutively
active (Sokołowska & Nowak, 2005). So, one possible
mechanism of action may be the blockage of native b-adren-
ergic stimulation. Moreover, a ligand’s pharmacologic effi-
cacy, or its ability to produce an effect, may not be fully
explained by its ability to stimulate a single receptor-mediated
signaling pathway. Previous studies have demonstrated that
stimulating a receptor with a ligand can expose different
intrinsic effects on various effectors systems (reviewed in
Kenakin, 1995; Urban et al., 2007). It has been also reported
that after ligand binding many receptors such as b2-ARs can
exist in multiple ‘‘active’’ conformations. These variable
conformations may reveal various different cellular responses
and may help clarify the diverse signaling profiles (Ghanouni
et al., 2001; Swaminath et al., 2005). Wisler et al. (2007)
characterized diverse signaling profiles of non-selective
b-blocker carvedilol, and postulated that ligand bias may
play a role in determining the effectiveness of b-AR
antagonists targeting 7TMRs.
Furthermore, various factors including histological origin
of cells, hormone dependency, and intracellular cell signaling
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pathways, as well as physicochemical properties of drugs may
contribute to the differential effects of these b-blockers on
non-stimulated cells. Liu et al. (2008) studied interaction of
b2-ARs with EGFR, and demonstrated that ICI118,551 was
more effective than atenolol in inhibiting EGFR-stimulated
cAMP increase in esophageal cancer cells. EGF increases
cAMP level by stimulating AC, and cAMP affect downstream
pathways via kinase A. EGFR signal transduction pathway is
directly involved in processes related to tumor prognosis like
angiogenesis, invasion and metastasis, and resistance to
apoptosis.
Tumor cell migration and invasion, the prerequisite for
metastasis development, are not only merely genetically
determined but are also distinctly environmentally regulated
(Guo et al., 2009). The ability to invade extracellular
matrices plays an important role in metastasis, and in
supplying blood flow to tumors. In this study, we evaluated
effects of AR antagonists on the invasiveness and migration
properties of MCF7, HepG2, and HT-29 cell lines. The
findings form the Boyden chamber assay demonstrated that
both propranolol and ICI118,551 significantly inhibited
invasion of non-stimulated cancer cells (Table 2).
Atenolol, in contrast, caused 4–7% non-significant reduc-
tions in invasion of all three cell lines. Likewise, ICI118,551
was shown to be more potent than metaprolol, another b1-
blocker, in inhibiting invasion of non-stimulated pancreatic
cancer cells after 20 h of application via CREB, NFkB, and
AP-1 pathways (Zhang et al., 2010). In contrast, Drell et al.
(2003) and Lang et al. (2004) reported that ICI118,551 and
atenolol did not affect invasion of non-stimulated mammary
and prostate carcinoma cells. However, their application
concentrations and durations were considerably lower than
that of the present study and the study of Zhang et al. (2010)
(i.e., 1 and 10 mM ICI118,551 and atenolol were applied for
12 and 20 h, respectively). In fact, concentrations empirically
determined in the present study were compatible to appli-
cation periods. In contrast, propranolol was more effective
than b1- and b2-selective adrenoceptor blockers in the
inhibition of invasiveness of MCF7 and HT-29 cells, in
parallel to the results of other reports obtained with different
cell lines (Lang et al., 2004; Masur et al., 2001). In previous
in vitro studies, it has been shown that propranolol
completely blocked norepinephrine-mediated invasiveness
of ovarian and prostate cancer, although alone it had no
effect on invasiveness of in these cells (Palm et al., 2006;
Sood et al., 2006). b-ARs can enhance production of MMP-
2 and MMP-9, and propranolol diminishes invasiveness of
cells by MMP2 and MMP9 inhibition as well as VEGF and
p38/MAPK (Guo et al., 2009; Huang et al., 2012). In fact,
propranolol alone was found to inhibit VEGF production and
MMP2 activity in human leukemic cell lines (Hajighasemi
& Hajighasemi, 2009).
It was reported that propranolol inhibited the promigratory
effect of norepinephrine and reduced metastases formation in
BALB/c nude mice (Palm et al., 2006). Wound healing and
tumor progression both involve similar processes such as cell
proliferation, inflammation, and angiogenesis (Lee et al.,
2009). One of the important characters related to process of
tumor cell penetration is motility. Our findings from the
in vitro scratch assay demonstrated that propranolol, atenolol,
and ICI118,551 reduced migration of MCF7, HT-29, and
HepG2 cells to varying extents depending on the application
concentration and duration (Figure 2). About 24 h of incuba-
tion with propranolol and atenolol were effective for inhibition
of MCF7 migration, whereas longer incubation periods were
required to observe inhibitory effect of ICI118,551 on cell
migration. Increasing concentrations of propranolol and
atenolol affected in vitro wound healing of HT-29 cells at
different incubation periods. WH of ICI118,551 applied HT-
29 cells did not differ with varying incubation periods. All
antagonist treatments except for the 24 h propranolol treat-
ments caused reduction in WH of HepG2 cells, and inhibitions
were concentration-independent (except for the 24 h atenolol
treatments). In a recent study, it has been demonstrated that
propranolol administration alone inhibited migration and
invasiveness of epithelial progenitor cells via Akt and
MAPK/ERK pathway (Zou et al., 2013). In the current
study, the administration of propranolol alone inhibited both
invasiveness and migration of cancer cells depending on the
cell type, application concentration, and time. Conclusively,
propranolol and ICI118,551 were found to be more effective
than atenolol in inhibiting both invasion and migration of non-
stimulated MCF7 and HT-29 cells. In particular, ICI118,551
was the most potent inhibitory agent of invasion.
On one hand, the more potent effect of ICI118,551 on cells
demonstrates involvement of b2-AR and its downstream
signalling pathways. On the other hand, the action of second
messengers, phosphorylation of effectors, downstream tran-
scriptional events, and regulation of cell cycle seem to happen
in a cell type-specific manner. For example, both angiogen-
esis and signaling through the RAF/MEK/ERK cascade play
critical roles in the development of HCC. In addition to being
highly angiogenic, human HCC tumors have high expression
and enhanced activity of MAP kinase (Schmidt et al., 1997).
Therefore, inhibition of both angiogenesis and RAF/MEK/
ERK signaling may cause high sensitivity of HepG2 cells to
ICI118,551. In addition, mutational status of any of the
downstream effector proteins of cancer cell lines may affect
the sensitivity of cells to ICI118,551. Even cells of different
origins may express a mutated b2-AR receptor rendering it
less responsive to antagonists.
Finally, b2-selective adrenoceptor blockage seems to be
more effective for non-stimulated cells. Furthermore, the
effect of the selective antagonists may show variation
depending on the concentration and incubation period, as
well as histological origin of cells. b1-Selective blockers may
act through cAMP/PKA pathway, whereas in addition to
cAMP/PKA, RAS, MAPK, NFkB, and AP-1 act in concert in
b2-selective blockage of the inhibition of invasion (Schuller,
2002; Weddle et al., 2001). Pharmacoepidemiological studies
support the suggestion that b-blockers could provide a clinical
benefit through inhibition of the prometastatic effects of b-AR
signaling on the tumor microenvironment. The use of agents
for tumor remodeling, such as b-blockers, in combination
with chemotherapeutic drugs may be a promising therapeutic
strategy to treat patients with solid tumors.
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